Sunday, March 26, 2023, Tampa, Florida, 11:45 AM – 1:15 PM Eastern Time

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian Cancer

Part 1 of a 2-Part CME Symposium Series Held in Conjunction with the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer®

Location
Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511

Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch
11:45 AM – 1:15 PM — Educational Meeting

Meeting Room
Ballroom B – Level 1


This event will also be webcast live.
Please see Registration tab for details.
There is no fee to participate in this event. For the in-person symposium in Tampa, preregistration is required as seating is limited.  
 
Faculty
Mansoor Raza Mirza, MD
Chief Oncologist
Copenhagen University Hospital
Medical Director
Nordic Society of Gynaecological Oncology – Clinical Trial Unit
Vice President, European Society of Gynaecological Oncology
Copenhagen, Denmark

Amit M Oza, MD
Bergsagel Chair in Medical Oncology
Professor of Medicine
University of Toronto
Head, Division of Medical Oncology and Hematology
Director, Clinical Cancer Research and BRAS Drug Development Program
Princess Margaret Cancer Centre
UHN and Mount Sinai Health System
Toronto, Ontario, Canada


Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Moderator
Joyce F Liu, MD, MPH
Associate Chief and Director of Clinical Research
Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, and Novocure Inc.
Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch Buffet
11:45 AM – 1:15 PM — Educational Meeting

MODULE 1: Optimal Genomic Evaluation of and Targeted Therapies for Newly Diagnosed Advanced Ovarian Cancer — Dr Mirza

  • Incidence of somatic and germline BRCA1/2 alterations and homologous recombination deficiency (HRD) in patients with advanced ovarian cancer
  • Current role of next-generation sequencing and germline sequencing in advanced ovarian cancer; available testing platforms
  • Efficacy and safety findings from Phase III studies (eg, SOLO-1, PRIMA, PRIME, PAOLA-1) supporting the use of olaparib, niraparib and olaparib/bevacizumab maintenance for patients with newly diagnosed advanced ovarian cancer
  • Optimal integration of PARP inhibitor maintenance regimens into treatment for advanced ovarian cancer; current role for patients with and without BRCA1/2 mutations and HRD positivity
  • Recently presented efficacy and safety findings from the Phase III ATHENA-MONO study assessing rucaparib as first-line maintenance therapy; impact of recent FDA actions on the developmental timeline for up-front rucaparib maintenance
  • Findings from the Phase II OVARIO study assessing maintenance niraparib/bevacizumab after front-line platinum-based chemotherapy/bevacizumab for advanced ovarian cancer; potential clinical role

MODULE 2: PARP Inhibitors for Relapsed/Refractory Ovarian Cancer — Dr Oza

  • Impact of first-line PARP inhibitor use on the selection and sequencing of later-line therapies for recurrent ovarian cancer
  • Optimal integration of genomic testing for recurrent ovarian cancer; incidence and clinical significance of BRCA reversion mutations
  • Key findings from the Phase IIIb OReO study evaluating the clinical utility of rechallenge with a PARP inhibitor in patients who have experienced disease progression on or after prior PARP inhibitor therapy; implications for later-line treatment
  • Long-term follow-up data, including overall survival findings, from clinical trials evaluating niraparib, olaparib and rucaparib for platinum-sensitive and platinum-resistant recurrent ovarian cancer
  • Rationale for the voluntary withdrawal of various later-line PARP inhibitor indications; ramifications for routine practice

MODULE 3: Rationale for and Available Data with PARP Inhibitors in Combination with Other Anticancer Therapies for Advanced Ovarian Cancer — Dr Liu

  • Biologic rationale for combining PARP inhibitors with immune checkpoint inhibitors for advanced ovarian cancer
  • Key efficacy results from early-phase studies (eg, TOPACIO, MOONSTONE) evaluating PARP inhibitors combined with anti-PD-1/PD-L1 antibodies
  • Rationale for the evaluation of VEGF inhibition as a component of novel combination strategies; early results (eg, MEDIOLA, OPAL trials) with PARP inhibitor, immune checkpoint inhibitor and bevacizumab triplet therapy
  • Adverse events associated with the combination of PARP inhibitors and immune checkpoint inhibitors with or without bevacizumab
  • Ongoing clinical trials combining PARP inhibitors and immunotherapy in the first-line setting (eg, ATHENA-COMBO, DUO-O, FIRST); potential role of this approach

MODULE 4: Novel Agents for the Treatment of Ovarian Cancer — Dr Penson

  • Biologic rationale for targeting folate receptor alpha in ovarian cancer; mechanism of action of mirvetuximab soravtansine
  • Published efficacy and safety outcomes from the Phase III SORAYA study of mirvetuximab soravtansine for platinum-resistant ovarian cancer with high folate receptor alpha expression
  • Recent FDA approval and current clinical role of mirvetuximab soravtansine for advanced ovarian cancer
  • Ongoing trials evaluating mirvetuximab soravtansine for advanced ovarian cancer
  • Rationale for targeting NaPi2b in ovarian cancer; available data with upifitamab rilsodotin (UpRi) for patients with advanced pretreated disease
  • Ongoing trials currently enrolling patients to receive UpRi for advanced platinum-sensitive and platinum-resistant ovarian cancer
  • Mechanism of action of tumor treating fields and biologic rationale for their use in combination with chemotherapy for platinum-resistant ovarian cancer
  • Early-phase efficacy and safety data with tumor treating fields in combination with chemotherapy for advanced ovarian cancer; ongoing Phase III INNOVATE-3 study
  • Other promising novel agents and strategies for advanced ovarian cancer

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider available clinical research with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer, and counsel appropriate patients regarding personalized treatment recommendations.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for recurrent ovarian cancer in order to optimally incorporate these agents into the care of appropriate patients.
  • Appreciate the biologic rationale for and published clinical research with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for ovarian cancer management.
  • Recognize the rationale for targeting folate receptor alpha in ovarian cancer, and determine optimal methods to test for this newly relevant biomarker and the current role of novel approaches to therapeutically exploit it.
  • Appreciate the incidence of sodium-dependent phosphate transport protein 2b expression in ovarian cancer, and evaluate published research findings with and ongoing clinical trials assessing investigational agents designed to exploit this potential therapeutic target.
  • Describe the scientific rationale for tumor treating fields as a therapeutic approach for patients with ovarian cancer, and appraise the available efficacy and safety data with this strategy delivered in combination with chemotherapy for recurrent, advanced disease.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for ovarian cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Oza has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Mirza — Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Zai Lab; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Zai Lab; Nonrelevant Financial Relationship: Chairman 2020-2022, European Network of Gynaecological Trial Groups. Dr Penson — Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Nonrelevant Financial Relationship: BMJ Publishing Group Ltd, Elsevier, UptoDate, Wiley-Blackwell, Wolters Kluwer Health.

MODERATOR — Joyce F Liu, MD, MPH – Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GSK, Regeneron Pharmaceuticals Inc; Consulting Agreement: Bristol-Myers Squibb Company; Trial Support (to Institution for Study Conduct): 2X Oncology Inc, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, GSK, Impact Therapeutics, Regeneron Pharmaceuticals Inc, Vigeo Therapeutics, Zentalis Pharmaceuticals.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, and Novocure Inc.

Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511

Meeting Room
Ballroom B – Level 1

Directions
The Tampa Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.

 
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. LIMITED SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:15 AM ET on Sunday, March 26th. If you are interested in attending, please visit our registration desk located at the Tampa Convention Center – Ballroom B ( Level 1).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Notice To Attendees:
  • Pre-registrants are guaranteed seating up until the program start time. Please have your confirmation email with QR Code ready when you arrive to check-in for the program.
  • For all other onsite/stand by attendees, we will accommodate onsite attendees for seating on a first-come-first-serve basis. Clinicians in practice will be prioritized.
  • Please note, “onsite/stand by registration” does not guarantee seating and participation in meal service.
  • Registration for this event is independent of registration for the 2023 SGO Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.